| Title: |
Using BCG Vaccine to Enhance Nonspecific Protection of Health Care Workers During the COVID-19 Pandemic: A Randomized Controlled Trial. |
| Authors: |
Madsen, Anne Marie Rosendahl, Schaltz-Buchholzer, Frederik, Nielsen, Sebastian, Benfield, Thomas, Bjerregaard-Andersen, Morten, Dalgaard, Lars Skov, Dam, Christine, Ditlev, Sisse Bolm, Faizi, Gulia, Azizi, Mihnaz, Hameed, Zainab Nadhim, Johansen, Isik Somuncu, Kofoed, Poul-Erik, Krause, Tyra Grove, Kristensen, Gitte Schultz, Loekkegaard, Ellen Christine Leth, Mogensen, Christian Backer, Mohamed, Libin, Oedegaard, Emilie Sundhaugen, Ostenfeld, Anne |
| Source: |
Journal of Infectious Diseases; 2/15/2024, Vol. 229 Issue 2, p384-393, 10p |
| Subject Terms: |
MEDICAL personnel, COVID-19 pandemic, BCG vaccines, RANDOMIZED controlled trials, COVID-19 |
| Abstract: |
Background The BCG (Bacillus Calmette-Guérin) vaccine can induce nonspecific protection against unrelated infections. We aimed to test the effect of BCG on absenteeism and health of Danish health care workers (HCWs) during the coronavirus disease 2019 (COVID-19) pandemic. Methods A single-blinded randomized controlled trial included 1221 HCWs from 9 Danish hospitals. Participants were randomized 1:1 to standard dose BCG or placebo. Primary outcome was days of unplanned absenteeism. Main secondary outcomes were incidence of COVID-19, all-cause hospitalization, and infectious disease episodes. Results There was no significant effect of BCG on unplanned absenteeism. Mean number of days absent per 1000 workdays was 20 in the BCG group and 17 in the placebo group (risk ratio, 1.23; 95% credibility interval, 0.98–1.53). BCG had no effect on incidence of COVID-19 or all-cause hospitalization overall. In secondary analyses BCG revaccination was associated with higher COVID-19 incidence (hazard ratio [HR], 2.47; 95% confidence interval [CI], 1.07–5.71), but also reduced risk of hospitalization (HR, 0.28; 95% CI,.09–.86). The incidence of infectious disease episodes was similar between randomization groups (HR, 1.09; 95% CI,.96–1.24). Conclusions In this relatively healthy cohort of HCWs, there was no overall effect of BCG on any of the study outcomes. Clinical Trials Registration NCT0437329 and EU Clinical Trials Register (EudraCT number 2020-001888-90). [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Infectious Diseases is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
